Finally, the role of tumor-infiltrating B cells (TIBs) is even more controversial: CD20+ TIBs have been shown to behave as APCs with an anti-tumorigenic effect in non-small-cell lung cancer (NSCLC), ovarian cancer [10,11] and in melanoma, as part of the tertiary lymphoid structures (TLS) associated with CD8+ T-lymphocytes [12]. Here, CD8A is linked to non-small cell lung carcinoma.